Clinical Trial Goal
To find out:
- The highest dose of CD30.CAR-EBVST that's safe to give
- If CD30.CAR-EBVST is safe and works well to treat lymphoma that has relapsed or is refractory in children and adults
You may be able to join this trial if you:
- Are 12 - 75 years old
- Have 1 of the following types of lymphoma that has relapsed or is refractory:
- Anaplastic T-cell lymphoma (ATCL)
- Diffuse large B-cell lymphoma (DLBCL)
- Extranodal NK/T-cell lymphoma
- Hodgkin lymphoma
- Peripheral T-cell lymphoma (PTCL)
- Post-transplant lymphoproliferative disease (PTLD)
- Have lymphoma cells with CD30 marker. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CD30.CAR-EBVST are created from Epstein Barr virus (EBV)-specific T cells from a donor that target CD30 on certain cells. CAR stands for chimeric antigen receptors and T stands for T cells, a type of immune cell. Doctors think this treatment will help find and destroy cancer cells.
In this trial, you’ll be placed in 1 of 2 groups depending on if you've had a blood or marrow transplant (BMT) recently:
In this trial, you’ll be placed in 1 of 2 groups depending on if you've had a blood or marrow transplant (BMT) recently:
- Group 1 – Have not had a BMT recently
- Group 2 – Have had a BMT recently
If you're in Group 1, you’ll first get standard chemotherapy (chemo) with 2 of drugs:
- Cyclophosphamide – Given as intravenous (IV) infusions
- Fludarabine – Given as IV infusions
Both groups will get CD30.CAR-EBVST given to you through an IV infusion that lasts 10 minutes. The dose of CD30.CAR-EBVST you’ll get depends on when you start the trial and how safe it has been.
The clinical trial doctors will watch you closely over the first 3 hours. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 5 years.
The Food and Drug Administration (FDA) has approved cyclophosphamide and fludarabine to treat lymphoma. The FDA has not yet approved CD30.CAR-EBVST.
Contacts
Carlos Ramos, MD, 832-824-4817, caramos@bcm.edu
Vicky Torrano, (832) 824-7821, vtorrano@bcm.edu-
Locations
Houston Methodist HospitalRECRUITING
Houston, Texas
Carlos Ramos, MD, (713) 441-1450, caramos@bcm.edu
Texas Children's HospitalRECRUITING
Houston, Texas
Carlos Ramos, MD, (713) 441-1450, caramos@bcm.edu
Sponsors
collaborator: The Methodist Hospital Research Institute, lead: Baylor College of Medicine
